Current Edition


Improving Treatment Options in Schizophrenia: Considering the Whole Patient

This severe psychiatric disorder is twice as prevalent as
Alzheimer’s disease and five times as prevalent as multiple
sclerosis. But despite available treatments, schizophrenia is
still a chronic, disabling illness, with symptoms that remain
untreated by marketed medications. However, as Alexandria
Wise-Rankovic of INC Research argues, among psychiatric
disorders, the therapeutic indication of schizophrenia has
the most medicines currently in development, many of which
target formulation improvements, novel mechanisms of
action, and unmet patient needs. And the newer treatments in
schizophrenia may eventually address the whole patient.